FDA approves trailblazing postpartum depression therapy, in crucial milestone for women's health
In a landmark decision, the US health regulator has approved the first treatment for mothers suffering from postpartum depression (PPD), a common but often overlooked and stigmatized complication of childbirth that affects an estimated 1 in 7 women.
The manufacturer of the injectable treatment — Sage Therapeutics $SAGE — has been busy, raising more than half a billion dollars through the sale of its stock to support the commercial rollout of the drug, hiring a 180-strong salesforce and setting up select centers for women to get administered with the one-time treatment under medical supervision.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.